We will use the next-generation sequencing (NGS) technology to identify genomic alterations of Taiwanese HPV positive and negative oropharyngeal squamous cell carcinoma (OPSCC) for novel biomarker development and the study design of potential clinical trials or translational research.
In the past decade, next-generation sequencing (NGS) technology has enabled cancer genome sequencing in screening and searching for new cancer genes in an efficient manner. This massive sequencing technique not only help to identify new altered genes for novel biomarker development, but also reveal gene alterations sensitive or resistant to specific therapies. Because the difference of genomic profiling between Taiwanese HPV positive and negative OPSCC is not clear yet, we propose this multi-center research project to address this issue. In this study, we will collect tumor tissues and clinical information from patients with OPSCC and create a platform for data storage and sharing.
Study Type
OBSERVATIONAL
Enrollment
410
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan
RECRUITINGKaohsiung Veterans General Hospital
Kaohsiung City, Taiwan
RECRUITINGChina Medical University Hospital
Taichung, Taiwan
To enroll a total of 300 patients with OPSCC who fit the criteria of this study in the enrolled period
To enroll a total of 300 patients with OPSCC who fit the criteria of this study in the enrolled period
Time frame: 5 years of proposed observation period
To perform next generation sequencing analysis of OPSCC tumor tissues
To perform next generation sequencing analysis of OPSCC tumor tissues
Time frame: 5 years of proposed observation period
Collect clinical data of OPSCC
To correlate with the clinical characteristics and treatment outcomes of patients with the genetic profile in Taiwan.
Time frame: 5 years of proposed observation period
To compare the difference of the genetic and molecular profiles among patients with HPV positive and negative OPSCC
To compare the difference of the genetic and molecular profiles among patients with HPV positive and negative OPSCC
Time frame: 5 years of proposed observation period
To compare the difference of genetic and molecular profiles between early (stage I and II) and advanced stage (stage III and IV) of HPV positive OPSCC
To compare the difference of genetic and molecular profiles between early (stage I and II) and advanced stage (stage III and IV) of HPV positive OPSCC
Time frame: 5 years of proposed observation period
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Taichung Veterans General Hospital
Taichung, Taiwan
RECRUITINGNational Cheng Kung University Hospital
Tainan, Taiwan
RECRUITINGPei-Jen Alex Lou
Taipei, Taiwan
RECRUITINGTaipei Veterans General Hospital
Taipei, Taiwan
RECRUITING